Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.
about
A phase I and pharmacokinetic study of intraperitoneal topotecanA phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors.A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors.Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administrationA multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumorsA new lipid-based nano formulation of vinorelbineTime-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy.Moving the Frontiers of Cancer Chemotherapy for Solid Tumors by Changing the Scope of Drug Development.Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.Topotecan, an active new antineoplastic agent: review and current status.Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.Oral topotecan: bioavailablity and effect of food co-administrationMarqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies.Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer.Tumor regression achieved by encapsulating a moderately soluble drug into a polymeric thermogelPhase I clinical trial of topotecan and pegylated liposomal doxorubicin.Current perspectives on camptothecins in cancer treatmentSchedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines.A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia.A Phase I trial of weekly docetaxel and topotecan for solid tumors.Achieving High Drug Loading and Sustained Release of Hydrophobic Drugs in Hydrogels through In Situ Crystallization.Clinical pharmacology of camptothecins.Antitumour activity of DX-8951f: a new camptothecin derivative.
P2860
Q28366214-C6F4E95C-652B-4723-AECC-C9A2F451775DQ33338244-8EA67C52-355D-4C0D-9427-2D65789DFDD4Q33339062-42BA1C19-A361-4FF0-84E3-817A0FEA621FQ33495553-7DD8EE92-B641-495E-94F4-261E7D499A2BQ33924277-F1AC4889-4DD2-415A-B97D-D2B79F794E5CQ34265212-F09838B6-419A-4D14-8365-114E01146AE0Q35053993-808D4648-7A9E-4628-B1D5-7A03F1224216Q36074388-76AEC0D3-D5C9-405E-A778-0E29A5B574F7Q36135270-80D5D703-E14E-4546-8E07-B9652B8D6BE3Q36179765-02014E1C-2705-428B-B274-F51583080E89Q36422757-23FC6AD2-753E-470E-927C-4CD80AE50E64Q36431807-DB64CB0D-4C01-4334-85B2-2456970CFCC1Q36620382-3E8862A0-B687-4934-BAF0-899AFD0B1496Q36629939-25DFE832-F8A8-49DF-A3DE-588B8A908FCCQ36695817-E0462342-3EB2-428E-89F9-AC44F4C2A390Q37036934-9FD347D1-4C79-4B16-A421-874693B11D98Q37159547-E3FD2469-19B0-4FF2-9D2B-8EA6EB1A1BABQ38871242-D29F20C3-82F2-49FA-BDFB-23C704A7A549Q38979496-6475DCEF-437C-4B4B-8087-D9A55857C8FBQ40490161-CCD02740-3D0C-48DB-8F36-A7A514857870Q42715927-A5192FA4-4DC0-4558-8C0D-E62B8DF9C004Q43201995-7223238B-1D7C-4665-8748-75BC41883D84Q44598660-536DB29A-4F79-4518-B498-F786F48B86F0Q46981461-6F3C34E3-918A-4FEB-8CD9-7DD864A360A9Q50750308-45A45B51-BD30-41D6-9FF7-B271D14BDEAEQ53780736-7B6BED51-79E2-435C-8119-63674E07D53CQ53852785-A1100F99-5AFC-4991-B2BB-66E96B2950AC
P2860
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Activity of topotecan, a new t ...... colony-forming units in vitro.
@en
Activity of topotecan, a new t ...... colony-forming units in vitro.
@nl
type
label
Activity of topotecan, a new t ...... colony-forming units in vitro.
@en
Activity of topotecan, a new t ...... colony-forming units in vitro.
@nl
prefLabel
Activity of topotecan, a new t ...... colony-forming units in vitro.
@en
Activity of topotecan, a new t ...... colony-forming units in vitro.
@nl
P2093
P356
P1476
Activity of topotecan, a new t ...... colony-forming units in vitro.
@en
P2093
Burris HA 3rd
Hanauske AR
Hilsenbeck SG
Johnson RK
Marshall MH
Von Hoff DD
P304
P356
10.1093/JNCI/84.23.1816
P407
P577
1992-12-01T00:00:00Z